Heart failure & cardiomyopathies

Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy

Eur Heart JPublished Open-label extension study

Authors' conclusion

Long-term mavacamten treatment resulted in sustained improvements in cardiac function and symptoms in patients with obstructive HCM, with no new safety concerns identified. Transient, reversible reductions in LVEF were observed in a small proportion of patients during long-term follow-up.

Study context

Population
Patients with obstructive hypertrophic cardiomyopathy (HCM) who completed EXPLORER-HCM211 (91.3%) still on mavacamten
Participants
231 patients
Outcome
Change from baseline to Week 180
Follow-up
Week 180
Methodological details5-year, ongoing, Median (range) time on study 166.1 (6.0-228.1) weeks; 185 (80.1%) and 99 (42.9%) completed Week 156 and 180 visits
  • 5-year
  • Ongoing
  • Median (range) time on study 166.1 (6.0-228.1) weeks; 185 (80.1%) and 99 (42.9%) completed Week 156 and 180 visits

Main finding

As reported in the abstract

Resting LVOT gradient, mean (SD) change
−40.3 (32.7) mmHg
Valsalva LVOT gradient, mean (SD) change
−55.3 (33.7) mmHg
NT-proBNP, median (IQR) change
−562 (−1162.5, −209) ng/L
EQ-5D-5L score, mean (SD) change
0.09 (0.17)
Improved by ≥1 NYHA class
74 (77.9%) of 95

Further findings

OutcomeValues
DeathAll considered unrelated to mavacamtenMavacamten 2.2%

Mean left ventricular ejection fraction (LVEF)

Baseline
73.9%
Week 24
66.6%
Week 180
63.9%

Death (all considered unrelated to mavacamten)

Deaths
Five (2.2%)

Safety

Transient LVEF reduction to <50% with temporary treatment interruption (all recovered LVEF ≥50%) · over 739 patient-years exposure

Patients with transient LVEF <50% (22 events)
20 patients (8.7%)
Exposure-adjusted incidence
2.77/100 patient-years
  • All recovered LVEF of ≥50%

Original publication

Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy. Eur Heart J. Published 1 September 2024. doi:10.1093/eurheartj/ehae579

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.